Q-omics provides the consensus-scored LOX profile across patient tissues and cancer cell-line models. LOX expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LOX is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, LOX protein abundance shows 27,131 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where LOX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LOX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LOX survival associations across molecular data types. LOX RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LOX RNA expression–survival associations across cancer types. High LOX expression shows unfavorable associations in MESO, STAD, BLCA, CESC, KICH and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LOX RNA expression.
This table summarizes LOX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LOX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LOX shows higher tumor expression in KIRC, HNSC, STAD, COAD, LIHC and LUAD. The KIRC box plot shows higher LOX RNA expression in tumor versus normal tissue (log2 FC = +4.292, t-test p < 0.001).
This table shows molecular features associated with LOX in patient tissues and cancer cell lines. In patient samples, LOX shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LOX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Myeloma.
